Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma

被引:5
|
作者
Carr, Rebecca A. [1 ]
Hsu, Meier [2 ]
Harrington, Caitlin A. [1 ]
Tan, Kay See [2 ]
Bains, Manjit S. [1 ]
Bott, Matthew J. [1 ]
Ilson, David H. [3 ]
Isbell, James M. [1 ]
Janjigian, Yelena Y. [3 ]
Maron, Steven B. [3 ]
Park, Bernard J. [1 ]
Rusch, Valerie W. [1 ]
Sihag, Smita [1 ]
Wu, Abraham J. [4 ]
Jones, David R. [1 ]
Ku, Geoffrey Y. [3 ]
Molena, Daniela [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
CROSS regimen; esophageal adenocarcinoma; FOLFOX; induction; positron emission tomography-directed chemoradiation; COMPLETE PATHOLOGICAL RESPONSE; ESOPHAGOGASTRIC JUNCTION; PREOPERATIVE CHEMORADIOTHERAPY; NEOADJUVANT CHEMORADIOTHERAPY; TUMOR-REGRESSION; SURVIVAL; CHEMOTHERAPY; CANCER; CARCINOMA; THERAPY;
D O I
10.1097/SLA.0000000000005163
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To compare the efficacy and safety of induction FOLFOX followed by PET-directed nCRT, induction CP followed by PET-directed nCRT, and nCRT with CP alone in patients with EAC. Summary of Background Data: nCRT with CP is a standard treatment for locally advanced EAC. The results of cancer and leukemia group B 80803 support the use of induction chemotherapy followed by PET-directed chemo-radiation therapy. Methods: We retrospectively identified all patients with EAC who underwent the treatments above followed by esophagectomy. We assessed incidences of pathologic complete response (pCR), near-pCR (ypN0 with >= 90% response), and surgical complications between treatment groups using Fisher exact test and logistic regression; disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method and evaluated using the log-rank test and extended Cox regression. Results: In total, 451 patients were included: 309 (69%) received induction chemotherapy before nCRT (FOLFOX, n = 70; CP, n = 239); 142 (31%) received nCRT with CP. Rates of pCR (33% vs. 16%, P = 0.004), near-pCR (57% vs. 33%, P < 0.001), and 2-year DFS (68% vs. 50%, P = 0.01) were higher in the induction FOLFOX group than in the induction CP group. Similarly, the rate of near-pCR (57% vs. 42%, P = 0.04) and 2-year DFS (68% vs. 44%, P < 0.001) were significantly higher in the FOLFOX group than in the no-induction group. Conclusions: Induction FOLFOX followed by PET-directed nCRT may result in better histopathologic response rates and DFS than either induction CP plus PET-directed nCRT or nCRT with CP alone.
引用
收藏
页码:E538 / E544
页数:7
相关论文
共 50 条
  • [21] More May Not Be Better: Comparison of Oncologic Outcomes Following Induction Chemotherapy Plus Chemoradiation and Chemoradiation Alone for Esophageal Adenocarcinoma
    Yee, Elliott J.
    Read, Jake
    Ziogas, Ioannis A.
    Stuart, Christina M.
    Olsen, Jeffrey
    Kim, Sunnie S.
    Mitchell, John D.
    Meguid, Robert A.
    McCarter, Martin D.
    Mungo, Benedetto
    JOURNAL OF SURGICAL ONCOLOGY, 2024,
  • [22] Neoadjuvant chemoradiation treatment of locally advanced adenocarcinoma of the duodenum
    Kluger, Y
    Soffer, D
    Sorid, D
    Michowitz, M
    Schreiber, L
    Klausner, JY
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2000, 2 (12): : 947 - 948
  • [23] Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
    Leichman, Cynthia Gail
    McDonough, Shannon L.
    Smalley, Stephen R.
    Billingsley, Kevin G.
    Lenz, Heinz-Josef
    Beldner, Matthew A.
    Hezel, Aram F.
    Velasco, Mario R.
    Guthrie, Katherine A.
    Blanke, Charles D.
    Hochster, Howard S.
    CLINICAL COLORECTAL CANCER, 2018, 17 (01) : E121 - E125
  • [24] Impact of Delaying Surgery After Chemoradiation on Outcomes for Locally Advanced Esophageal Squamous Cell Carcinoma
    Wong, Lye-Yeng
    Liou, Douglas Z. Z.
    Vitzthum, Lucas K. K.
    Backhus, Leah M. M.
    Lui, Natalie S. S.
    Chang, Daniel
    Shrager, Joseph B. B.
    Berry, Mark F. F.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (04) : 2212 - 2223
  • [25] Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma
    Sanchez-Izquierdo, Nuria
    Perlaza, Pilar
    Pages, Mario
    Buxo, Elvira
    Rios, Jose
    Rubello, Domenico
    Colletti, Patrick M.
    Mayoral, Maria
    Casanueva, Sebastian
    Fernandez-Esparrach, Gloria
    Gines, Angels
    Fuster, David
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 38 - 43
  • [26] Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer
    Hashimoto, Masashi
    Shirakawa, Yasuhiro
    Maeda, Naoaki
    Tanabe, Shunsuke
    Noma, Kazuhiro
    Sakurama, Kazufumi
    Katsui, Kuniaki
    Nishizaki, Masahiko
    Fujiwara, Toshiyoshi
    ESOPHAGUS, 2020, 17 (02) : 127 - 134
  • [27] Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study
    Elliott, Jessie A.
    Klevebro, Fredrik
    Mantziari, Styliani
    Markar, Sheraz R.
    Goense, Lucas
    Johar, Asif
    Lagergren, Pernilla
    Zaninotto, Giovanni
    van Hillegersberg, Richard
    Henegouwen, Mark I. van Berge
    Schafer, Markus
    Nilsson, Magnus
    Hanna, George B.
    Reynolds, John V.
    ANNALS OF SURGERY, 2023, 278 (05) : 692 - 700
  • [28] Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
    Ribi, Karin
    Koeberle, Dieter
    Schuller, Jan C.
    Honegger, Hanspeter
    Roth, Arnaud
    Hess, Viviane
    Moosmann, Peter
    von Moss, Roger
    Borner, Markus
    Lombriser, Norbert
    Pestalozzi, Bernhard
    Ruhstaller, Thomas
    SUPPORTIVE CARE IN CANCER, 2009, 17 (08) : 1109 - 1116
  • [29] Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma
    Reni, Michele
    Cereda, S.
    Balzano, G.
    Passoni, P.
    Rognone, A.
    Zerbi, A.
    Nicoletti, R.
    Mazza, E.
    Arcidiacono, P. G.
    Di Carlo, V.
    Villa, E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1253 - 1259
  • [30] Neoadjuvant chemoradiation versus adjuvant chemotherapy for locally advanced adenocarcinoma of the rectosigmoid junction
    Salami, A. C.
    Obaid, T.
    Nweze, N. J.
    Deleon, M.
    Force, L.
    Gorgun, E.
    Wexner, S.
    Joshi, A. R. T.
    COLORECTAL DISEASE, 2020, 22 (05) : 513 - 520